Differing levels of testosterone and the prostate: a physiological interplay

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature reviews. Urology

• Publication date

  2011-05-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrurol.2011.79PMID 21629220
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preoperative hypogonadism is not an independent predictor of high‐risk disease in patients undergoing radical prostatectomy

  2011cited by this paper
• Testosterone therapy in men with untreated prostate cancer.

  2011cited by this paper
• Reviews

  2011cited by this paper
• Androgen Replacement Therapy After Prostate Cancer Treatment

  2010cited by this paper
• Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging

  2010cited by this paper
• Identification of late-onset hypogonadism in middle-aged and elderly men.

  2010cited by this paper
• Adverse events associated with testosterone administration.

  2010cited by this paper
• Low serum testosterone and increased mortality in men with coronary heart disease

  2010cited by this paper
• Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.

  2010cited by this paper
• Intermittent androgen suppression for prostate cancer

  2010cited by this paper
• Testosterone replacement therapy following radical prostatectomy.

  2009cited by this paper
• The benefits and risks of testosterone replacement therapy: a review

  2009cited by this paper
• A Manual of 2008 ISA, ISSAM, EAU, EAA and ASA Recommendations: Investigation, Treatment and Monitoring of Late-onset Hypogonadism in Males.

  2009cited by this paper
• Absence of relationship between steroid hormone levels and prostate cancer tumor grade.

  2009cited by this paper
• Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.

  2009cited by this paper
• Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review

  2009cited by this paper
• ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males

  2009cited by this paper
• Testosterone therapy and prostate carcinoma

  2009cited by this paper
• Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?

  2009cited by this paper
• Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.

  2008cited by this paper
• Investigation, treatment and monitoring of late-onset hypogonadism in males

  2008cited by this paper
• Low serum testosterone and mortality in older men.

  2008cited by this paper
• Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study.

  2008cited by this paper
• Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes.

  2008cited by this paper
• Testosterone for the aging male; current evidence and recommended practice

  2008cited by this paper
• Androgen replacement in men undergoing treatment for prostate cancer.

  2008cited by this paper
• Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy

  2007cited by this paper
• Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship.

  2007cited by this paper
• Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.

  2007cited by this paper
• Locally advanced prostate cancer—biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate‐specific antigen recurrence after radiotherapy

  2007cited by this paper
• Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.

  2007cited by this paper
• Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.

  2007cited by this paper
• Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research

  2007cited by this paper
• Locally advanced prostate cancer: Biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate‐specific antigen recurrence after radiotherapy

  2007cited by this paper
• Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men.

  2006cited by this paper
• Low serum testosterone and mortality in male veterans.

  2006cited by this paper
• Association of specific symptoms and metabolic risks with serum testosterone in older men.

  2006cited by this paper
• Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells.

  2006cited by this paper
• Prostate-specific antigen: update 2006.

  2006cited by this paper
• Prostate cancer risk in testosterone-treated men.

  2006cited by this paper
• Testosterone replacement therapy and the risk of prostate cancer. Is there a link?

  2006cited by this paper
• PROSTATE‐SPECIFIC ANTIGEN TESTING IN HYPOGONADISM: IMPLICATIONS FOR THE SAFETY OF TESTOSTERONE‐REPLACEMENT THERAPY

  2006cited by this paper
• Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.

  2006cited by this paper
• Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?

  2006cited by this paper
• Characterization of androgen-regulated expression of CYP3A5 in human prostate.

  2006cited by this paper
• Testosterone and prostate cancer: an historical perspective on a modern myth.

  2006cited by this paper
• Circulating Steroid Hormones and the Risk of Prostate Cancer

  2006cited by this paper
• Testosterone replacement therapy and the risk of prostate cancer: a perspective view

  2005cited by this paper
• Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.

  2005cited by this paper
• Testosterone as a predictor of pathological stage in clinically localized prostate cancer.

  2005cited by this paper
• Testosterone replacement therapy in hypogonadal men and prostate cancer risk

  2005cited by this paper
• Prostate cancer in men using testosterone supplementation.

  2005cited by this paper
• Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.

  2005cited by this paper
• Testosterone replacement therapy after primary treatment for prostate cancer.

  2005cited by this paper
• MEDICAL PROGRESS: RISKS OF TESTOSTERONE REPLACEMENT THERAPY AND RECOMMENDATIONS FOR MONITORING

  2004cited by this paper
• Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

  2004cited by this paper
• Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.

  2004cited by this paper
• High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study

  2004cited by this paper
• Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.

  2004cited by this paper
• Diabetes mellitus and risk of prostate cancer (United States)

  2004cited by this paper
• Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study.

  2004cited by this paper
• Oestrogens and prostate cancer.

  2003cited by this paper
• Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.

  2003cited by this paper
• Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel

  2003cited by this paper
• Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.

  2003cited by this paper
• Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan.

  2003cited by this paper
• Reduced risk of prostate cancer among patients with diabetes mellitus

  2002cited by this paper
• Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.

  2002cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.

  2002cited by this paper
• Leptin is associated with increased prostate cancer risk: a nested case-referent study.

  2001cited by this paper
• Is the flare phenomenon clinically significant?

  2001cited by this paper
• Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

  2001cited by this paper
• Testosterone dose-response relationships in healthy young men.

  2001cited by this paper
• Hormones and prostate cancer: what's next?

  2001cited by this paper
• Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.

  2001cited by this paper
• Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels.

  2001cited by this paper
• The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.

  2001cited by this paper
• Effects of testosterone replacement in hypogonadal men.

  2000cited by this paper
• Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.

  2000cited by this paper
• Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.

  2000cited by this paper
• The role of steroid hormones in prostate carcinogenesis.

  2000cited by this paper
• Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate.

  1999cited by this paper
• Effect of testosterone treatment on bone mineral density in men over 65 years of age.

  1999cited by this paper
• Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.

  1999cited by this paper
• Androgen-Induced Regrowth in the Castrated Rat Ventral Prostate: Role of 5α-Reductase1.

  1999cited by this paper
• Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.

  1999cited by this paper
• In Reply: RE:THE RELATIONSHIP BETWEEN PROSTATIC INTRAEPITHELIAL NEOPLASIA AND PROSTATE CANCER CRITICAL ISSUES

  1998cited by this paper
• Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men.

  1998cited by this paper
• Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

  1998cited by this paper
• Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation.

  1998cited by this paper
• Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk.

  1997cited by this paper
• Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

  1997cited by this paper
• The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.

  1997cited by this paper
• The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction.

  1997cited by this paper
• Prostate cancer after exogenous testosterone treatment for impotence.

  1997cited by this paper
• Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis.

  1997cited by this paper
• Prospective study of sex hormone levels and risk of prostate cancer.

  1996cited by this paper
• Prostate volume in testosterone‐treated and untreated hypogonadal men in comparison to age‐matched normal controls

  1994cited by this paper
• A ten-year safety study of the oral androgen testosterone undecanoate.

  1994cited by this paper

• Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study

  2024cites this paper
• Safety of androgen therapy in men with prostate cancer.

  2022cites this paper
• Potential Protective Effects of Testosterone Therapy on Prostate Cancer

  2022cites this paper
• Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.

  2022cites this paper
• The role of testosterone in men’s health: is it time for a new approach?

  2022cites this paper
• Association between interleuleukin-1β polymorphism (rs16944) and biomarkers levels in Iraqi patients with prostate cancer

  2022cites this paper
• Engineered reproductive tissues

  2020cites this paper
• Attenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats

  2018cites this paper
• Androgenic modulation of AR-Vs

  2018cites this paper
• Low Testosterone Alters the Activity of Mouse Prostate Stem Cells

  2017cites this paper
• Relationship Between Aerobic Fitness, the Serum IGF-1 Profiles of Healthy Young Adult African American Males, and Growth of Prostate Cancer Cells

  2017cites this paper
• Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives

  2017cites this paper
• Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes.

  2016cites this paper
• Role of Macrophages in the Development of Castration-Resistant Prostate Cancer

  2016cites this paper
• Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids

  2015cites this paper
• Testosterone Replacement Therapy in Hypogonadal Men Following Prostate Cancer Treatment: A Questionnaire-Based Retrospective Study among Urologists in Bavaria, Germany

  2015cites this paper
• The safety of testosterone supplementation therapy in prostate cancer

  2014cites this paper
• The treatment of late-onset hypogonadism.

  2014cites this paper
• Hormonersatzbehandlung in der Andropause - Nutzen und Risiken

  2014cites this paper
• Anabolic/Androgenic Steroids in Skeletal Muscle and Cardiovascular Diseases

  2013cites this paper
• Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.

  2013cites this paper
• Diabetes Protects from Prostate Cancer by Downregulating Androgen Receptor: New Insights from LNCaP Cells and PAC120 Mouse Model

  2013cites this paper
• Association of serum calcium with serum sex steroid hormones in men in NHANES III

  2013cites this paper
• Epidemiological studies of diet quality, body size and prostate cancer risk

  2013cites this paper
• Études des différences sexuelles dans les changements de concentrations de la globuline de liaison des hormones sexuelles en réponse à l'alimentation méditerranéenne

  2012cites this paper
• Stimulation of a non-functioning pituitary macroadenoma after administration of goserelin acetate for locally advanced prostate cancer causing a sustained elevation in PSA and testosterone.

  2012cites this paper
• Testosterone Replacement Therapy and Prostate Health

  2012cites this paper
• Androgens, diabetes and prostate cancer.

  2012cites this paper
• Testosterone treatment in the aging male: myth or reality?

  2012cites this paper